Related Experiment Video
Updated: Aug 10, 2026
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
Published on: September 14, 2009
[New strategies in the treatment of restenosis]
E von Hodenberg1, B Tost, T Scheffold
1Klinik für Innere Medizin/Kardiologie Herzzentrum Lahr/Baden, Lahr.
Insights
Coronary angioplasty (PTCA) restenosis remains a challenge, affecting 35-50% of patients. Radiotherapy shows promise for treating in-stent restenosis and other forms.
Area of Science:
- Interventional Cardiology
- Vascular Biology
- Medical Technology
Background:
- Coronary angioplasty (PTCA) has been used for over two decades.
- Restenosis, or renarrowing of the artery, affects 35-50% of patients within six months of PTCA.
- Preventing restenosis is a significant challenge in interventional cardiology.
Purpose of the Study:
- To review the challenges in inhibiting restenosis after coronary angioplasty.
- To evaluate the effectiveness of various treatment modalities for restenosis.
- To explore the potential of radiotherapy as a treatment for in-stent restenosis.
Main Methods:
- Review of existing literature on PTCA and restenosis.
- Analysis of systemic drug therapy, various angioplasty methods, local drug/gene delivery, and stenting.
- Assessment of radiotherapy's role in managing restenosis.
Main Results:
- Systemic drugs and alternative angioplasty methods have not significantly reduced restenosis.
- Local drug and gene therapies show efficacy only in animal models.
- Stents reduce restenosis but can develop in-stent restenosis.
- Radiotherapy appears promising for severe in-stent restenosis and potentially other forms.
Conclusions:
- Despite advances, restenosis post-PTCA remains a critical issue.
- Current pharmacological and mechanical interventions have limitations.
- Radiotherapy presents a promising therapeutic option for managing complex restenosis, particularly within stents.
Abstract:
Twenty-three years after introduction of coronary angioplasty (PTCA), the inhibition of restenosis formation continues to be the major challenge for the interventional cardiologist. About 35-50% of all patients undergoing PTCA develop a renarrowing of the intravascular lumen within the following six months. The use of specific systemic drug therapy as well as different angioplastic methods (rotablation, atherectomy, laser angioplasty) all failed to significantly reduce restenosis. Local drug delivery and local gene therapy have only shown to be effective in animal experiments. Restenosis can be reduced by the use of stents; however restenosis can also develop within the stents. The treatment of choice for severe in-stent restenosis may become radiotherapy, which seems to be a promising tool also for other forms of restenosis.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:27Peripheral Artery Disease III: Interprofessional Care